DS
GYRE icon

David Shaw’s Gyre Therapeutics GYRE Stock Holding History

David Shaw’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,316
Closed -$41K – 5502
2022
Q1 		$41K Sell
8,316
-10,375
-56% -$51.4K ﹤0.01% 5191
2021
Q4 		$128K Buy
+18,691
New +$320K ﹤0.01% 5006
2020
Q1 		– Sell
-8,263
Closed -$422K – 4055
2019
Q4 		$422K Buy
+8,263
New +$346K ﹤0.01% 3481
2019
Q3 		– Sell
-3,027
Closed -$167K – 3886
2019
Q2 		$167K Sell
3,027
-706
-19% -$44.1K ﹤0.01% 3495
2019
Q1 		$227K Buy
3,733
+386
+12% +$24.8K ﹤0.01% 3347
2018
Q4 		$198K Buy
3,347
+1,267
+61% +$93.4K ﹤0.01% 3552
2018
Q3 		$168K Buy
+2,080
New +$165K ﹤0.01% 3577
2016
Q2 		– Sell
-356
Closed -$67K – 3403
2016
Q1 		$67K Sell
356
-283
-44% -$68.2K ﹤0.01% 3314
2015
Q4 		$225K Sell
639
-305
-32% -$120K ﹤0.01% 3507
2015
Q3 		$495K Sell
944
-18
-2% -$27.4K ﹤0.01% 3064
2015
Q2 		$2.11M Buy
962
+27
+3% +$54.1K ﹤0.01% 2171
2015
Q1 		$2.19M Hold
935
– – ﹤0.01% 1940
2014
Q4 		$1.94M Buy
935
+84
+10% +$162K ﹤0.01% 2316
2014
Q3 		$1.7M Buy
851
+165
+24% +$408K ﹤0.01% 2363
2014
Q2 		$2.44M Sell
686
-45
-6% -$147K ﹤0.01% 2156
2014
Q1 		$2.73M Buy
731
+60
+9% +$222K ﹤0.01% 2075
2013
Q4 		$2.19M Buy
671
+24
+4% +$94.6K ﹤0.01% 2441
2013
Q3 		$2.71M Buy
647
+23
+4% +$92.5K ﹤0.01% 2158
2013
Q2 		$2.1M Buy
+624
New +$2.37M ﹤0.01% 2069

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

David Shaw's GYRE Position: Q2 2022 in Review

David Shaw sold out of Gyre Therapeutics (GYRE) in Q2 2022, closing a stake of 8,316 shares — an estimated $41K sold.

David Shaw first reported a position in GYRE in Q2 2013 and held it in 19 quarters. The position peaked at $2.73M in Q1 2014. 41 funds tracked by Wall St. Rank hold GYRE as of Q2 2022.

  • David Shaw reported no remaining Gyre Therapeutics position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 8,316 Gyre Therapeutics shares in Q2 2022, an estimated $41K.
  • David Shaw first reported a position in Gyre Therapeutics in Q2 2013 and held it in 19 quarters.
  • David Shaw's Gyre Therapeutics position peaked at $2.73M in Q1 2014.
  • 41 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.